Blocklisting Interim Review

RNS Number : 8583K
Hutchison China Meditech Limited
30 June 2014
 



 

 

 

 

Hutchison China MediTech Limited ("Chi-Med")

(AIM: HCM)

 

Blocklisting Six Monthly Return

 

 

London: Monday, 30 June 2014: Chi-Med announces the following blocklisting six monthly return:

 

1.

Name of applicant:

 


Hutchison China MediTech Limited

2.

Name of scheme:

 


Hutchison China MediTech Limited Share Option Scheme

 

3.

Period of return:                                 

 


From 29 December 2013 to 28 June 2014

 

4.

Balance under scheme from previous return:

 


1,721,279 ordinary shares of US$1 each

 

5.

The amount by which the block scheme has been increased, if the scheme has been increased since the date of the last return:

 


Nil

6.

Number of securities issued/allotted under scheme during period:


845,000 ordinary shares of US$1 each





7.

Balance under scheme not yet issued/allotted at end of the period:

 


876,279 ordinary shares of US$1 each

8.

Number and class of securities originally listed and the date of admission:

 


2,560,606 ordinary shares of US$1 each admitted on 26 June 2007

9.

Total number of securities in issue at the end of the period:


52,896,448 ordinary shares of US$1 each





Name of contact:

 


Christian Hogg

Address of contact:

 


21/F., Hutchison House, 10 Harcourt Road, Hong Kong

 

Telephone number of contact:

 


+852 2121 8200

 

 

Ends

Enquiries

 

Chi-Med

Christian Hogg, CEO

Telephone:      +852 2121 8200

 



Panmure Gordon (UK) Limited

Telephone:      +44 20 7886 2500

Richard Gray

Andrew Potts

 

 



Citigate Dewe Rogerson

Anthony Carlisle

David Dible

Telephone:      +44 20 7638 9571

Mobile:             +44 7973 611 888

Mobile:             +44 7967 566 919

 

About Chi-Med

 

Chi-Med is a China-based healthcare group focused on researching, developing, manufacturing and selling pharmaceuticals and health-related consumer products.  Its China Healthcare Division manufactures, markets and distributes prescription and over-the-counter pharmaceuticals in China.  Its Drug R&D Division focuses on discovering and developing innovative therapeutics in oncology and autoimmune diseases.  Its emerging Consumer Products Division focuses on organic and natural consumer products in Asia.

 

Chi-Med (LSE:HCM) is majority owned by the multinational conglomerate Hutchison Whampoa Limited (SEHK:13).  For more information, please visit: www.chi-med.com.

 


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
BLRKMGFVKGDGDZG
UK 100

Latest directors dealings